Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. LITE
4. PLTR
5. REGN
6. MRVL
7. ABBV
8. CL
9. CHKP
10. SPY

Go back to Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

October 31, 2024 6:54 PM EDT

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the companys New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).

The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in... More